© Reuters. FILE PHOTO: The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS/Rachel Wisniewski
(Reuters) – AstraZeneca (NASDAQ:AZN)’s COVID-19 vaccine was only slightly less effective against the variant first found in India than the strain identified in Kent, the company’s Chief Executive Officer Pascal Soriot said in an interview with Financial Times on Friday.
He added the company is in talks with governments, including the United Kingdom, about new contracts for booster doses.
AstraZeneca’s COVID vaccine slightly less effective against variant found in India, CEO tells FT
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.